All News

sheila Tweet
RHEUMarampa
Tofa for RA by the grp of Dr. Atul Deodhar: >Tofa(56%) vs. pbo(29.4%)-significant improvement in ASAS20 at wk 16 >Primary & secondary endpts met >No new safety signals reported @Rheumnow #ACR20 https://t.co/G9U5cCQU7K
Janet Pope Tweet
Janetbirdope
What would you use in multidrug failure RA pt from last tweet +RF nodules & keratitis failed 2 TNFi & 2 JAKi @RheumNow #ACR20 @CRASCRRheum
David Liew Tweet
drdavidliew
Low-dose steroids in RA: what's the harm, right? (You probably know where I'm going with this) ESPOIR 10y data: total events, and severe infections worse with dose and time (cumulative 8.4g ≡ 5mg/d) No doubt some residual confounding, but real risk! #ACR20 ABST1998 @RheumNow https://t.co/BAQmOR1ped
Janet Pope Tweet
Janetbirdope
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse. @RheumNow @CRASCRRheum https://t.co/9cTS1tNE42
Richard Conway Tweet
RichardPAConway
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained. Good response to reintroduction of TNFi @rheumnow #ACR20 Abstr#2010 https://t.co/Ki7PTsetbH
Eric Dein Tweet
ejdein1
Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp
Eric Dein Tweet
ejdein1
2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm
k dao Tweet
KDAO2011
Which DMARD would you use in an RA pt Rx naive pt with mod dz activity and who has RA lung dz? #acr20 @RheumNow
k dao Tweet
KDAO2011
Which JAKi will you use after MTX failure? #acr20 @rheumnow
k dao Tweet
KDAO2011
Which biologic will you use after MTX and TNF failure for RA pts? #acr20 @rheumnow
sheila Tweet
RHEUMarampa
Large cohort of older RA pts newly rx w/HCQ or MTX: 👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ. @RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/ZnDuMhTMYF
×